MNG703
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HYPOXIA+0.248
- GLYCOLYSIS+0.150
- BILE_ACID_METABOLISM+0.148
- KRAS_SIGNALING_DN+0.137
- ESTROGEN_RESPONSE_EARLY+0.072
- MYOGENESIS+0.040
- ESTROGEN_RESPONSE_LATE+0.005
- HEDGEHOG_SIGNALING-0.006
- HEME_METABOLISM-0.017
- WNT_BETA_CATENIN_SIGNALING-0.025
Top 10 suppressed
- E2F_TARGETS-0.490
- INTERFERON_ALPHA_RESPONSE-0.439
- G2M_CHECKPOINT-0.437
- OXIDATIVE_PHOSPHORYLATION-0.424
- MYC_TARGETS_V1-0.415
- IL6_JAK_STAT3_SIGNALING-0.394
- INFLAMMATORY_RESPONSE-0.392
- ALLOGRAFT_REJECTION-0.377
- INTERFERON_GAMMA_RESPONSE-0.377
- MYC_TARGETS_V2-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-W8-A86G-01A-21R-A36F-07 | — | A | 0.851 |
| 2 | MDT-AP-0029 | Med | Medulloblastoma | 0.848 |
| 3 | SRR1516067 | — | — | 0.842 |
| 4 | BS_90B22NGP | ATRT | — | 0.841 |
| 5 | 8ef24f8e-03c4-4db0-a136-7381346e9836 | — | — | 0.840 |
| 6 | SRR1313097 | — | A | 0.836 |
| 7 | BS_0Y66ZBWE | low-grade glioma | — | 0.833 |
| 8 | MDT-AP-1261 | Med | Medulloblastoma | 0.832 |
| 9 | TCGA-J2-A4AD-01A-11R-A24H-07 | — | cohortA1 | 0.830 |
| 10 | SRR1379562 | GTEX | — | 0.822 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HYPOXIA | 0.248 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.148 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.137 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.072 | Inavolisib | — uncovered |
| MYOGENESIS | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.005 | Idelalisib | — uncovered |